We scan new podcasts and send you the top 5 insights daily.
Target antigen loss or modulation on tumor surfaces is a frequent mechanism of resistance following CD19 CAR-T or CD20 bispecific antibody failure. Dr. Budde highlights that treating relapsed patients with further targeted therapy without a biopsy frequently leads to treatment failure, as tumors often become CD19- or CD20-negative. Re-biopsying is vital to confirm target presence before initiating next-line therapies.
Dr. Patrick Baeuerle argues the biggest challenge for cell engagers and CAR-T therapies is not killing power but the tumor's ability to down-regulate or lose the target antigen. This heterogeneity is a fundamental escape mechanism that future multi-targeting strategies must address to prevent relapse.
An exploratory strategy for DLBCL patients involves using ctDNA to detect minimal residual disease after CAR T-cell therapy. This allows for early intervention with bispecific antibodies when the disease burden is low, potentially preventing full clinical progression, a shift from reactive to proactive treatment.
A key hesitation in adopting the tafasitamab-lenalidomide-R-CHOP regimen is the theoretical risk of CD19 antigen loss. If a patient becomes refractory, their eligibility and the efficacy of subsequent CD19-targeted CAR T-cell therapy could be compromised, influencing upfront treatment decisions.
Unlike some targeted therapies that lead to antigen loss, treatment with the CD19-directed antibody tafasitamab does not appear to eliminate CD19 expression on lymphoma cells. This is a critical finding, as it preserves the target for subsequent potent therapies like CD19-directed CAR T-cells.
Cancers evolve under therapeutic pressure, often developing new resistance mutations. Re-testing the tumor via tissue or liquid biopsy upon progression is essential, as it can identify acquired mutations that make the cancer susceptible to a different, next-generation targeted therapy, extending patient survival.
A key clinical concern with CD19-directed therapies is antigen loss, which could prevent future CAR T-cell treatments. Data from the INMIND trial alleviates this fear, showing that 23 of 24 post-treatment lymphoma samples retained CD19 expression, suggesting tofacitimab does not preclude subsequent CAR-T therapy.
Rather than viewing bispecific antibodies and CAR-T cell therapy as mutually exclusive, Dr. Budde uses bispecific combinations as an off-the-shelf bridging strategy. High tumor burden and refractory disease reduce CAR-T response rates; administering an initial truncated course of bispecific combinations debulks aggressive lymphoma into deep remissions before transitioning patients to single-infusion CAR-T to complete treatment.
Before initiating a CD20-targeting bispecific antibody in patients who have failed CAR-T therapy, a new biopsy is mandatory. Up to 30% of these patients experience CD20 antigen loss, which would render the bispecific therapy ineffective and necessitates choosing a drug with a different target.
In heavily pretreated relapsed/refractory follicular lymphoma, it's crucial to perform a tumor biopsy to check for CD20 expression before choosing a CD20-targeting bispecific antibody. Prior treatments can lead to loss of the antigen, which would render the bispecific ineffective.
Because CD20 x CD3 bispecific antibodies require CD20 target engagement, antigen downregulation or loss is a primary resistance mechanism in patients experiencing early relapse. Dr. Elizabeth Budde highlights that verifying CD20 expression via repeat biopsy is clinically mandatory prior to initiating bispecific treatment or determining post-relapse therapy, ensuring the target antigen remains present on lymphoma cells.